HDV-I is under clinical development by Diasome Pharmaceuticals and currently in Phase II for Type 2 Diabetes. According to GlobalData, Phase II drugs for Type 2 Diabetes have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HDV-I’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HDV-I (Hepatic-directed vesicles loaded with insulin) is under development for the treatment of type I and type II diabetes. It is administered through subcutaneous route. HDV-I is injectable short acting insulin is a parenteral version of short-acting, mealtime insulin. The drug candidate is developed based on HDV insulin technology using liposomal constructs.
Diasome Pharmaceuticals overview
Diasome Pharmaceuticals (Diasome) is a pharmaceutical company. It focuses on clinical and commercial development of therapies for diabetes and obesity. The company’s pipeline products include multiple injected and oral formulations of liver targeted insulin’s for both type 1 and type 2 diabetic patients. Diasome’s products include oral HDV insulin, injectable HDV insulin and oral HDV candidates among others. The company’s technology platform Hepatocyte directed vesicle (HDV), a cell targeting system which helps to deliver a wide range of necessary hormones and drugs to the liver. It offers products in the fields of insulin replacement, and hepatic (liver) glucose metabolism. Diasome is headquartered in Cleveland, Ohio, the US.
For a complete picture of HDV-I’s drug-specific PTSR and LoA scores, buy the report here.